Skip to main content

1 Result(s)

within Medicine & Public Health Remove this filter Cancer Research Remove this filter Oncology Remove this filter Bryan K. Kee Remove this filter

and

  1. Article

    Open Access

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

    Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or co...

    Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran… in Cancer Chemotherapy and Pharmacology (2023)

    Download PDF (647 KB) View Article